Abbott's Galectin-3 Test Provides Doctors in Europe with New Tool for
Assessing the Prognosis of Chronic Heart Failure Patients
ABBOTT PARK, Illinois, April 10, 2013
-- Galectin-3 test may help physicians identify patients at highest risk for a
worse prognosis, including re-hospitalization and death, allowing them to
tailor the level of care to individual patient needs
ABBOTT PARK, Illinois, April 10, 2013 /PRNewswire/ -- Abbott today announced
CE Marking (Conformite Europeenne) for the ARCHITECT Galectin-3 assay, a test
to aid doctors in assessing the prognosis of patients diagnosed with chronic
heart failure (HF). The test was developed in partnership with BG Medicine,
Inc., (NASDAQ: BGMD) to run on Abbott's ARCHITECT immunochemistry platform.
"Galectin-3reflects the pathophysiology of heart failure and is one of the
most powerful prognostic indicators in heart failure. It helps clinicians
identify which patients are at high risk for worsening heart failureearly in
the course of their disease," saidDr. Rudolf de Boer, Associate Professor in
Cardiology at the University Medical Centre Groningen, the Netherlands.
"Knowing which patients are at increased risk of hospital readmission –
independent of other variables – could provide physicians with important
information to help them reach different decisions about treatment, which may
benefit patient care."
Heart failure, or the inability of the heart to circulate blood effectively,
is associated with poor patient outcomes, a lower quality of life, and
recurrent and costly health services.[2, 3] While the progress of HF is
different for each patient, several studies demonstrate that HF patients with
higher levels of a protein called galectin-3 present are more likely to have
worse outcomes, including re-hospitalization and death.
"Despite numerous medical advances, the number of deaths among hospitalized
heart failure patients remains high, exceeding that of most cancers," said
Brian Blaser, executive vice president, Diagnostics Products, Abbott. "The new
ARCHITECT Galectin-3 test is a helpful tool to aid physicians in their care of
these critically ill patients."
The ARCHITECT Galectin-3 test is available in several European countries.
Intended Use The ARCHITECT Galectin-3 assay is a chemiluminescent
microparticle immunoassay (CMIA) for the quantitative determination of
galectin-3 in human serum and EDTA plasma on the ARCHITECT i System. The
ARCHITECT Galectin-3 assay may be used in conjunction with clinical evaluation
as an aid in assessing the prognosis of patients diagnosed with chronic heart
About BG Medicine BG Medicine, Inc., (Nasdaq: BGMD) is a diagnostics company
focused on the development and commercialization of novel cardiovascular tests
to address significant unmet medical needs, improve patient outcomes and
reduce healthcare costs. The Company has two products: the BGM Galectin-3®
test for use in patients with chronic heart failure is available in the United
States and Europe; and the CardioSCORE™ test for the risk prediction of major
cardiovascular events will be launched in Europe in the first half of 2013.
For additional information about BG Medicine, heart failure and galectin-3
testing, please visit www.bg-medicine.com and www.galectin-3.com .
About Abbott Diagnostics Abbott is a global leader in in vitro diagnostics and
offers a broad range of innovative instrument systems and tests for hospitals,
reference labs, molecular labs, blood banks, physician offices and clinics.
With more than 22,000 customers in more than 100 countries, Abbott's
diagnostic products offer customers automation, convenience, bedside testing,
cost-effectiveness, and flexibility. Abbott has helped transform the practice
of medical diagnosis from an art to a science through the company's commitment
to improving patient care and lowering costs.
About Abbott Abbott is a global healthcare company devoted to improving life
through the development of products and technologies that span the breadth of
healthcare.With a portfolio of leading, science-based offerings in
diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals, Abbott serves people in more than 150 countries and employs
approximately 70,000 people.
Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.
 de Boer, R, Voors, A, Muntendam, P, et al. Galectin-3: A novel mediator of
heart failure development and progression. European Journal of Heart Failure
2009; 11: 811-817. McMurray, JJV, Adamopoulos, S, Anker, SD et al. ESC
Guidelines for the diagnosis and treatment of acute and chronic heart failure
2012. European Heart Journal. 2012; 33: 1787–1847. Mosterd, A, Hoes, AW.
Clinical Epidemiology of Heart Failure. Heart. 2007; 93:1137–1146. de Boer,
R, Lok, D, Jaarsma, T, et al. Predictive value of plasma galectin-3 levels in
heart failure with reduced and preserve ejection fraction. Annals of Medicine
2011; 43: 60-68.
Contact: Darcy Ross, +1-(847)-937-3655; Jessica Masuga, +1-(847) 935-0650;
Financial:Tina Ventura, +1-(847) 935-9390
Press spacebar to pause and continue. Press esc to stop.